In a recent study, Ngo and coworkers reported an experimental strategy to effectively suppress melanoma metastasis in patient-derived xenografts, based on the simultaneous targeting of the tumor microenvironment using an anti-CD47 mAb (CD47 is expressed on all melanoma clinical samples, its expression being higher in metastatic than in primary tumors) and of melanoma cells using an anti-CD271 mAb [237]. Here, CD47 is linked to neoplasm.